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T-cell acute lymphoblastic leukemia (T-ALL) is frequently character-ized by glucocorticoid (GC) resistance, which is associated with infe-rior outcomes, thus highlighting the need for novel therapeutic
approaches for GC-resistant T-ALL. The pre-T-cell receptor (pTCR)/TCR
signaling pathways play a critical role in cell fate decisions during physio-
logical thymocyte development, with an interplay between TCR and glu-
cocorticoid receptor (GR) signaling determining the T-lymphocyte selection
process. We performed an shRNA screen in vitro and in vivo in T-ALL cell
lines and patient-derived xenograft (PDX) samples to identify vulnerabilities
in the pTCR/TCR pathway and identified a critical role for the lymphocyte
cell-specific kinase (LCK) in cell proliferation. LCK knockdown or inhibition
with dasatinib (DAS) caused cell cycle arrest. Combination of DAS with
dexamethasone (DEX) resulted in significant drug synergy leading to cell
death. The efficacy of this drug combination was underscored in a random-
ized phase II-like murine trial, recapitulating an early phase human clinical
trial. T-ALL expansion in immunocompromised mice was significantly
impaired using this drug combination, compared to mice receiving control
vehicle or single drug treatment, highlighting the immediate clinical rele-
vance of this drug combination for high-risk T-ALL patients. Our results
thus provide a strategy to improve the efficacy of current chemotherapy
platforms and circumvent GC resistance.
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ABSTRACT
Introduction
Current minimal residual disease (MRD)-stratified chemotherapy protocols for
patients with T-cell acute lymphoblastic leukemia (T-ALL) result in 5-year event-
free survival rates of 80% and 50% for pediatric and adult patients, respectively.1,2
Induction failure, early relapse, and isolated central nervous system (CNS) involve-
ment are more common in T- than B-lineage ALL.3 Moreover, resistance to conven-
tional chemotherapy including glucocorticoid (GC) is a frequent feature of relapsed
and refractory T-ALL, reducing the second remission rate and long-term outcomes.4
GC are an instrumental component of ALL therapy and induce apoptosis in lym-
phoid malignancies.5-7 Resistance to GC is a critical factor influencing treatment
response and outcome.5,8-11 Amongst ALL subtypes, GC resistance is more frequent-
ly observed in infant ALL and T-ALL.5,9,11,12
Endogenous GC can induce apoptosis during the selection process of T lympho-
cytes in the thymus, an effect which can be constrained by crosstalk with T-cell
receptor (TCR) signaling.13,14 Whilst mature T-cell maintenance requires tonic TCR
signaling, inappropriate TCR expression has been shown to give rise to T-cell
malignancies in mouse model systems.15,16
The immature pre-T-cell receptor (pTCR) consists of a complex of alpha (pTCRα)
and beta (TCRβ) peptide chains complexed with CD3de and CD3γe heterodimers.
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Activation of this complex occurs through the SRC family
kinase (SFK) members lymphocyte cell-specific protein-
tyrosine kinase (LCK) and FYN. They are critical modula-
tors of T-cell development and activation.17 LCK phospho-
rylates the plasma membrane-associated TCR complex18
and ZAP70.19 ZAP70 in turn phosphorylates the linker for
activation of T cells (LAT) leading to the activation of
downstream signaling cascades. The overall activity of
LCK is regulated by the phosphorylation status of the acti-
vating and inhibitory tyrosine residues 394 and 505,
respectively.20 LCK activation correlates with Y416SRC
(also Y394LCK) phosphorylation, as the latter over-rides
the inhibitory effects of Y505 phosphorylation.21
We hypothesized, therefore, that T-ALL continues to
rely on proliferative and survival stimuli inherent to the
TCR signaling pathway, which, if inhibited, may enhance
GC sensitivity. A targeted shRNA screen directed against
components of the TCR signaling initiation complex iden-
tified a crucial role for LCK in T-ALL proliferation, both in
vitro and in vivo. The anti-proliferative effects of LCK
knockdown could be replicated by using the small mole-
cule inhibitor dasatinib (DAS). Drug synergy was
observed using DAS in combination with dexamethasone
(DEX) on patient-derived xenograft (PDX) cell survival 
in vitro. Mirroring the design of early phase human trials, a
murine phase II-like trial demonstrated significantly
impaired leukemia progression in vivo using combination
treatment. Our results present a clear rationale for using
DAS in conjunction with DEX to enhance conventional




The patient-derived material was collected as part of diagnostic
investigations of patients at the Great North Children’s Hospital,
Department of Paediatric Haematology and Oncology, Newcastle
upon Tyne, UK. The material was collected and stored with
informed consent obtained from all subjects in accordance with
the Declaration of Helsinki. 
Samples with explicit written consent for in vivo studies were
requested from the Newcastle Biomedicine Biobank, Newcastle
University, UK, and used according to approvals given by the
Newcastle Biomedicine Biobank (NHB application NHB-008) and
the local institutional review board Newcastle & North Tyneside
Ethics Committee (REC reference: 07/H0906/109).
Drug matrix assays
Dasatinib (9 nM – 30 mM) (DC Chemicals, Shanghai, China)
was titrated on T-ALL cell lines (4x104/well) in 96-well plates
(Corning, NY, USA). Cell viability was assessed after 3 days using
Cell Counting Kit 8 (NBS Biologicals, Cambridgeshire, UK).
Absorbance was measured at OD450 nm using a POLARstar
Omega plate reader (BMG LABTECH, Bucks, UK). IC50 values
were determined by GraphPad Prism. Assays were performed in
triplicate and at least three independent repeats were performed.
For DAS/DEX combination treatments DAS (80 nM – 50 mM)
and DEX (0.09 nM – 600 nM) were titrated in 2-dimensions on 
T-ALL cell lines (4x104 cells per well in 96-well plate) or ex vivo
expanded PDX cells (8x104 cells per well in 96-well plate). Ex vivo
expansion was achieved after co-culture with OP9-DL1 for 1
week, after which cells were separated from their feeders by
repetitive transfer and subsequently plated. After 72 hours (h) of
culture, the plates were developed as above. Drug synergy was
determined using Combenefit software (v.2.021).22
Phase II-like murine trial
For each of the ten PDX samples, 8x106 cells were intrafemoral-
ly (IF) injected into four NSG mice (40 mice in total) under isoflu-
rane anesthesia. The four NSG mice derived from one PDX sam-
ple were matched for gender and age. T-ALL engraftment in
mouse peripheral blood was monitored weekly by tail vein bleeds
(20 mL blood/mouse). The four mice of each PDX were random-
ized to receive control vehicle, DAS (35 mg/kg), DEX (1 mg/kg) or
DEX/DAS combination by intraperitoneal (IP) injection upon
engraftment, defined as ≥0.5% peripheral blood hCD45+/hCD7+
cells. The median treatment duration of these mice was 15 days,
depending on their clinical status. When any of the four mice dis-
played signs of ill health or weight loss, all four mice derived from
this PDX were killed at the same time to assess leukemia engraft-
ment in bone marrow, blood, spleen, liver and CNS. Spleen size
and weight were recorded. Statistical analyses were performed
using RStudio (Boston, MA, USA) with linear mix model. The
final analysis excluded the four mice derived from patient sample
LK214, as all mice succumbed to T-ALL before treatment was ini-
tiated.
See the Online Supplementary Appendix for further details of the
methods used.
Results
A targeted shRNA screen of T-cell receptor pathway
components identifies an essential role for lymphocyte
cell-specific kinase in T-cell acute lymphoblastic
leukemia cell line and patient-derived xenograft 
proliferation in vitro
To explore the importance of the pTCR/TCR signaling
complex in proliferation and survival of malignant T cells,
we performed a limited shRNA screen targeting six genes
with three shRNAs per gene, including LCK, ZAP70,
PTCRA, FYN, CD3E and LAT in four T-ALL cell lines (HPB-
ALL, CUTLL1, MOLT4, SUPT1), and included 18 control
shRNAs (see Online Supplementary Methods and Online
Supplementary Table S1A). In silico analysis using the Cancer
Cell Line Encyclopedia (CCLE) demonstrated that these six
genes are highly expressed in a panel of T-ALL cell lines
(Online Supplementary Figure S1A). LCK and PTCRA expres-
sion was confirmed by targeted gene expression analysis in
T-ALL cell lines and patient samples (Figure 1B) (Online
Supplementary Figure S1B). The limited shRNA screen
revealed the shLCK#3 construct targeting LCK was the
only construct significantly depleted in all four cell lines,
when compared with base line shRNA integration, under-
lining an important role for LCK in T-ALL cell line prolifer-
ation and/or survival (Figure 1A and Online Supplementary
Figure S1C and D). The shLCK#1, shZAP70#1 and
shPTCRA#2 constructs were lost in 3 out of 4 cell lines.
Constructs targeting FYN, CD3E, or LATwere significantly
depleted in one cell line only, suggesting that these mole-
cules do not play an universal role in T-ALL cell prolifera-
tion. ShRNAs against essential ribosomal genes were pre-
dictably depleted, whilst all three shRNA constructs target-
ing the tumor suppressor PTENwere enriched as expected.
Repeated sampling at 16, 30 and 40 days after transduction
demonstrated progressive depletion of shRNA constructs
targeting LCK and ZAP70 (Online Supplementary Table S2
and Online Supplementary Figure S1E). PDX LK203 showed
good viability (≥75%) and proliferation potential (Td = 2.8
days) in co-culture with human mesenchymal stem cells
(hMSC), hence subjected to shRNA screening. ShRNA
sequencing 30 days after transduction confirmed all con-
structs targeting LCK were significantly depleted (Figure
1A, Online Supplementary Table S3 and Online Supplementary
Figure S1F).
Knockdown of lymphocyte cell-specific kinase in T-cell
acute lymphoblastic leukemia cell lines confirms an
essential role for lymphocyte cell-specific kinase 
in vitro propagation
To confirm the role of LCK and other components of the
pTCR/TCR signaling complex in cell proliferation, com-
petitive outgrowth assays were performed. SUPT1,
MOLT4 and CUTLL1 cells were transduced with lentiviral
shRNAs targeting LCK, ZAP70, FYN, PTCRA or non-tar-
geting control shRNAs. Successfully transduced cells
expressing green fluorescence protein (GFP) were seeded
in a 1:1 ratio with parental cells. 
Three shRNAs were used to silence LCK, of which
shLCK#3 achieved the greatest degree of knockdown.
Lentiviral knockdown with shLCK#3 led to significant
reduction in mRNA in SUPT1 (75%KD), MOLT4 (55%
KD), and CUTLL1 (45% KD) cells (Figure 2A). In general,
greater knockdown was associated with more pro-
nounced impairment of in vitro proliferation (Online
Supplementary Figure S2A). LCK expression was confirmed
at protein level, demonstrating ubiquitous expression of
LCK in cell lines (Online Supplementary Figure S1G). In line
with mRNA downregulation, knockdown of LCK led to a
decrease in total LCK protein expression (Figure 2A). Non-
transduced cells consistently outcompeted LCK knock-
down cells resulting in a pronounced loss of over 70%
transduced GFP+ cells in all three cell lines, underlining the
critical and universal role of LCK in T-ALL cell line main-
tenance (Figure 2B and C, and Online Supplementary Figure
S2A and C). 
A similar but less significant observation was made for
ZAP70 knockdown in SUPT1, MOLT4 and CUTLL1 cells.
Efficient ZAP70 knockdown correlated with a pronounced
proliferation defect (Online Supplementary Figure S2A and
C). Knockdown of PTCRA affected proliferation in
pTCRα+ MOLT4 and SUPT1, but not in pTCRα- CUTLL1
(Online Supplementary Figure S2A and C). Moreover, FYN
knockdown did not affect proliferation in any of the cell
lines despite efficient knockdown (Online Supplementary
Figure S2B).
Knockdown of lymphocyte cell-specific kinase in T-cell
acute lymphoblastic leukemia cell lines and 
patient-derived xenograft samples impairs leukemia
propagation in vivo
To confirm a functional role for LCK in vivo, PDX L963
cells were transduced with our shRNA library and trans-
planted into six NSG mice (Figure 3A and Online
Y. Shi et al.
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Figure 1. A targeted shRNA screen reveals lymphocyte cell-specific kinase (LCK) is essential for in vitro proliferative potential. (A) T-cell acute lymphoblastic
leukemia (T-ALL) cell lines (SUPT1, MOLT4, HBP-ALL, CUTLL1) and PDX LK203 were subjected to a functional screen using a pLKO5-shRNA library containing 36 con-
structs targeting selected pre-T-cell receptor (pTCR)/TCR signaling complex components (PTCRA, CD3E, FYN, ZAP70, LCK, LAT), positive (PTEN, RPS29, RPL9), nega-
tive controls (KLHL7, CD19, DDB2, ERGIC3, FLG, RUNX1-ETO, SESN2, TRPM7) and a non-targeting control (NTC). Genomic DNA was sampled and barcoded. Enriched
and depleted shRNAs were identified by next generation sequencing (NGS). The heatmap depicts statistically significant gains (red) or losses (green) of shRNA con-
structs after in vitro culture of four T-ALL cell lines (40 days) and PDX LK203 (30 days). (B) Relative gene expression of LCK in seven cell lines and 12 PDX samples.
LCK expression was determined in four T-ALL cell lines, 697 and REH (B-lineage ALL cell lines [B-ALL]), TK6 (lymphoblastoid cell line), and 12 PDX samples by real
time quantitative-polymerase chain reaction. GAPDH served as reference gene for normalization.
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Supplementary Figure S3A). Genomic DNA (gDNA) was
extracted from L963 cells isolated from bone marrow and
spleen after mice became symptomatic (week 11). ShRNA
sequencing indicated that shLCK#3 represented the most
significantly depleted shRNA construct in vivo (Figure 3A,
Online Supplementary Table S3 and Online Supplementary
Figure S3B).
To assess the effect of LCK knockdown on engraftment
fitness, MOLT4 cells were transduced with lentiviral vec-
tors encoding either red fluorescent protein RFP/shNTC
(non-targeting control) or GFP/shLCK#3. Equal propor-
tions of cell populations were transplanted into NSG mice
(n=5). Leukemia cells were isolated from spleen, bone
marrow and liver once mice were symptomatic (day 26).
Flow cytometric analysis of the leukemic cell population
established that cells carrying shNTC had a clear compet-
itive engraftment advantage over cells with LCK knock-
down in all mice tissues sampled (Figure 3B and Online
Supplementary Figure S3C).
Knockdown of lymphocyte cell-specific kinase leads to
cell cycle arrest in T-cell acute lymphoblastic leukemia
cell lines and patient-derived xenograft samples
Next we investigated the mechanisms underlying the
defect in proliferation, survival and engraftment observed
after LCK knockdown. Jurkat, MOLT4 and SUPT1 cells
were transduced with shLCK#1/#3 and cell cycle analyses
performed. In all cell lines, we observed significant cell
cycle arrest with an increase in G0/G1 phase and decrease
in S phase after LCK knockdown (Figure 4A-C and Online
Supplementary Figure S4A). 
ShLCK#3 led to decreased protein levels of total LCK
and activated p-Y416SRC in cell lines, suggesting activation
status of LCK is associated with cell cycle arrest. In PDX
L963, LCK knockdown led to a 45% reduction in total
LCK expression, as well as a 71% reduction in p-Y416SRC
as assessed by Phosflow (Figure 4D). This knockdown
resulted in a decrease in S phase over time compared to
control (Online Supplementary Figure S4B). The proliferative
behavior of PDX cells was analyzed after labeling with cell
trace violet (CTV). PDX L963 cells were transduced with
shRNA constructs targeting LCK or a non-targeting con-
trol (NTC) and co-cultured with OP9-DL1 feeder cells for
13 days. The LCK knockdown cells showed restricted pro-
liferation compared to the control cells (Figure 4E).
Confirmatory siRNA knockdown of LCK was undertaken
in PDX samples LK203 and L963. Knockdown of total and
activated LCK was confirmed by Phosflow. Cell cycle
Figure 2.  Knockdown of lymphocyte cell-specific kinase (LCK) reduces propagation of T-cell acute lymphoblastic leukemia (T-ALL) cell lines in vitro. SUPT1 (A and
B) and MOLT4 (A and C) cells were lentivirally transduced with shNTC (non-targeting control), shLCK#1, shLCK#2, shLCK#3, shPTCRA#1, or shZAP70#1 expression
constructs. (A) Knockdown efficiency of LCK at mRNA level (left) and protein level (right) after 6 days. Whole cell lysates were probed for total LCK and GAPDH in
western blot analysis. (B and C) T-ALL cell lines SUPT1 (B) and MOLT4 (C) transduced with GFP-expressing shLCK (blue), shZAP70 (purple),  shPTCRA (red) or shNTC
(black) constructs were seeded in a 1:1 ratio with non-transduced parental cells in vitro. Cells were cultured and analyzed repetitively by flow cytometry for the pres-
ence of GFP+ cells over a time period of 30 and 40 days for SUPT1 and MOLT4, respectively. A relative GFP expression of 1 denotes a mixture of 50% GFP+ cells with
50% parental cells (ratio 1:1). A value of 0.5 refers to 25% of GFP+ cells and 75% parental cells (ratio 1:4).  Student's t-test: ****P<0.001.
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arrest was observed, corroborating our earlier findings
(Online Supplementary Figure S4C and D). 
Knockdown of LCK was analyzed for early apoptosis
induction in CUTLL1, MOLT4, SUPT1 and Jurkat.
Although a clear increase in Annexin V staining was
observed in MOLT4, suggesting LCK knockdown led to
apoptosis, this was not observed in CUTLL1, Jurkat or
SUPT1 (Online Supplementary Figure S4E). This suggests
that cell cycle arrest, rather than apoptosis induction, is
the predominant effect leading to diminished cell expan-
sion in vitro and reduced propagation in vivo after LCK
knockdown.
Tyrosine kinase inhibitor dasatinib blocks lymphocyte
cell-specific kinase function and leads to cell cycle
arrest while lymphocyte cell-specific kinase  activation
levels predict response to its inhibition
The tyrosine kinase inhibitor DAS is a dual SRC/ABL
inhibitor known to effectively inhibit LCK.21 The effect of
DAS on LCK protein expression and activation status was
assessed by western blot, after demonstrating near univer-
sal LCK activation as evidenced by tyrosine residue 416
phosphorylation in cell lines (Online Supplementary Figure
S1G). We confirmed that DAS effectively abolished acti-
vated p-Y416SRC in all four T-ALL cell lines tested, whilst
slightly decreasing total LCK protein levels. Furthermore,
dephosphorylation of inhibitory p-Y505LCK was noted, as
well as a decrease in p-Y783PLCγ1 and p-Y493ZAP70, two
downstream targets of LCK (Figure 5A and Online
Supplementary Figure S5A). As knockdown of LCK leads to
cell cycle arrest, we performed cell cycle analyses after
administration of DAS.  Cell cycle arrest was observed in
all six T-ALL cell lines tested, with a significant increase in
G0/G1 and decrease in S phase (Figure 5A and Online
Supplementary Figure S5B). In parallel, PDX cells supported
by in vitro co-culture with OP9-DL1 were exposed to DAS.
In line with our cell line data, DAS abolished activated 
p-Y416SRC levels in all six PDX samples (Figure 5B and
Online Supplementary Figure S5C) and cell cycle arrest was
observed in all three PDX samples tested (Figure 5B and
Online Supplementary Figure S5D).
The in vitro sensitivity of a panel of nine T-ALL cell lines
to DAS was determined. The IC50 observed ranged from 5
nM (HSB2) to 15 mM (MOLT16) (Figure 5C). The cell line
HSB2 not only demonstrated the highest sensitivity to
DAS but also the highest p-Y416SRC activation level as
determined by Phosflow. This observation can be
explained by the presence of a t(1;7)(p34;q34) transloca-
tion leading to LCK activation by TCRβ enhancer ele-
ments in HSB2. We thus hypothesized that the level of
activated LCK might represent a biomarker for DAS
responsiveness. Phosflow was used to quantify and calcu-
late the ratio between p-Y416SRC and total LCK. A strong
and significant correlation was observed between the IC50
for DAS and the ratio of activated Y416SRC in T-ALL cell
lines (R2=0.778, P=0.004) (Figure 5C). The sensitivity of
PDX cells to DAS ranged from GI50 of 23.8 nM to 19.7 mM
(median of 1.2 mM). However, in this setting, no signifi-
cant correlation between the GI50 and p-Y416
SRC/LCK ratio
was identified, suggesting that DAS sensitivity of patient-
derived cells is dependent on additional factors (Online
Supplementary Figure S5E).
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Figure 3. Loss of lymphocyte cell-specific kinase (LCK) negatively effects propagation potential of the T-cell acute lymphoblastic leukemia (T-ALL) cell line MOLT4
and patient-derived xenograft (PDX) L963 in vivo. (A) Volcano plot derived from the functional in vivo screen representing the magnitude of the fold change (log2) in
shRNA abundance derived from leukemia cells isolated from the spleen of PDX L963 on the x-axis. Each dot represents an individual shRNA construct. The y-axis
represents the significance in enrichment or depletion of shRNA constructs (log10 scale). Three dots (shLCK#3, shRPL9#1 and shCD19#2) above the blue line are
significantly depleted (P<0.05). Bar plot of the normalized shLCK#3 sequencing reads (log2) in leukemic cells derived from the bone marrow (orange) or spleen (blue)
of six individual mice (M1-6), relative to the frequency of these reads before transplantation (green, base line B1-3). (B) Schematic representation of the in vivo com-
petitive outgrowth assay. MOLT4 cells were lentivirally transduced with shNTC (red fluorescent protein, RFP) or shLCK#3 (GFP) and intrafemorally injected into five
NSG mice in a 1:1 ratio. Mice were culled once symptomatic and the ratio of RFP : GFP positive human leukemic cells in spleen (n=5), bone marrow (n=3) or liver
(n=3) determined by flow cytometry. In all mice, the MOLT4 cells carrying shLCK#3 were outcompeted by shNTC cells during engraftment in spleen, marrow and liver.
Student's t-test: *P<0.05, ***P<0.005, ****P<0.001.
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Dasatinib re-sensitizes dexamethasone resistance in 
T-cell acute lymphoblastic leukemia cell lines and
patient-derived xenograft samples
DAS leads to complete inhibition of p-Y416SRC and cell
cycle arrest in T-ALL cell lines and PDX cells, suggesting
that DAS treatment of T-ALL has a cytostatic effect. In
clinical practice, effective eradication of T-ALL relies on
the application of combinatorial treatment. LCK inhibi-
tion has previously been shown to sensitize chronic lym-
phoid leukemia (CLL) to DEX and induce cell death.23 We
thus went on to investigate potential synergy between
LCK inhibition and DEX, as DEX is universally used for
treatment of ALL. The cell viability of SUPT1 and
CUTLL1, in the presence of DEX, was evaluated after
knockdown of LCK. Whereas the cell viability of mock
transduced and non-targeting control cells was minimally
affected by DEX treatment, LCK knockdown increased
DEX sensitivity suggesting that LCK protein and/or activ-
ity levels play a crucial role in GC resistance (Figure 6A
and Online Supplementary Figure S6A). 
A more detailed analysis of the potency of the combina-
tion of DEX and LCK inhibition was examined by using
DAS instead of the LCK knockdown. DEX (0-600 nM) and
DAS (0-50 mM) were titrated along a dose matrix and cell
viability was determined. Synergy for individual drug
combinations was determined using Combenefit.22 The
matrix revealed drug synergy at concentrations which are
clinically achieved, i.e., 100 nM for DEX and 264 nM for
DAS (Figure 6B and Online Supplementary Figure S6B).24,25
Bioinformatic analysis of all ten T-ALL cell lines revealed a
statistically significant enrichment of drug synergy at clin-
ically relevant concentrations. This synergy was observed
at 8-110 nM of DEX and 0.223-4.5 µM of DAS (Online
Supplementary Figure S6C and D). 
Subsequently, PDX cells were expanded ex vivo for 1
week and exposed to the same drug combinations in dose
matrices. These assays verified the synergistic action of
DEX+DAS in a wide range of PDX cells, whilst confirming
that increased DAS concentrations and resultant LCK inhi-
bition augmented the response to DEX (Figure 6C and
Online Supplementary Figure S6E). Combined analysis of all
drug matrices with PDX cells again revealed a statistically
significant enrichment of drug synergy at clinically rele-
vant concentrations (Online Supplementary Figure S6F).
Moreover, the combination of DEX+DAS induced more
cell death compared with control vehicle or single drugs as
revealed by Annexin V/PI staining (Figure 6C).
DEX has a wide range of actions, including genomic and
non-genomic effects. Genomic effects are the result of
nuclear translocation of the GC receptor and subsequent
transactivation or repression of genes containing a GC
response element (GRE), as exemplified by the
Glucocorticoid-Induced Leucine Zipper (GILZ) gene.
Accordingly, we observed strong induction of GILZ gene
expression after DEX exposure in the T-ALL cell line
Jurkat and five PDX samples tested (Figure 6D and Online
Supplementary Figure S6G). This response was significantly
enhanced when combining DEX with knockdown of LCK
(Figure 6D) or DEX+DAS in a range of T-ALL cell lines and
PDX samples, suggesting that LCK inactivation augments
DEX-induced gene transcription and reverses DEX resist-
ance (Figure 6D and Online Supplementary Figure S6G).
Figure 4. Lymphocyte cell-specific kinase (LCK) knockdown leads to cell cycle arrest in T-cell acute lymphoblastic leukemia (T-ALL) cell lines and patient-derived
xenograft (PDX) cells. (A-C) Cell cycle status was determined by flow cytometry using Hoechst 33342 in cell lines Jurkat (A and C), MOLT4 (B and C), and SUPT1 (C)
7 days after transduction with shLCK#3 or shNTC expression vectors. (D) PDX L963 cells were lentivirally transduced with shLCK#3 or shNTC expression constructs.
Phosflow analysis of total LCK and p-Y416SRC was performed 8 days later. (E) shLCK#3 and shNTC transduced PDX L963 cells were loaded with CTV and cultured for
13 days. Flow cytometric analysis of CTV incorporation (cell divisions) was performed and demonstrated progressive reduction in cell number after 4-6 cell divisions
after LCK knockdown relative to control knockdown. Student's t-test: *P<0.05, **P<0.01, ***P<0.005.
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Phase II-like trial in vivo demonstrates significant
reduction in leukemia burden after combination 
treatment with dexamethasone and dasatinib
To test the efficacy of DEX and DAS in vivo, we conduct-
ed a phase II-like trial in mice (Figure 7A).26 Ten PDXs
were engrafted in four mice each. The four mice derived
from one single patient sample were randomly assigned to
treatment arms, namely control vehicle, DEX (1 mg/kg),
DAS (35 mg/kg) or DEX+DAS (1 mg/kg DEX + 35 mg/kg
DAS). After IF injection, mice tail vein blood was moni-
tored weekly for human CD7/CD45 and murine CD45
expression to monitor peripheral blood engraftment.
Representative PDX L809 commenced treatment 46 days
after injection for a total duration of 3 weeks; the four
mice were culled 72 days after injection (Figure 7B). L809
cells engrafted in the spleens of the four mice showed
greatly reduced levels of total LCK and dephosphorylation
of LCK (p-Y416SRC and p-Y505LCK) after DAS or DEX+DAS
combination treatment (Figure 7C). Western blot analysis
of positively selected viable human cells again demon-
strated decreased protein expression of LCK and p-Y416SRC
after DAS treatment. The number of residual viable
human cells after effective DEX+DAS treatment was not
sufficient to categorically confirm reduced protein expres-
sion (Online Supplementary Figure S7F). One mouse in the
DAS arm (LK080) developed uterine prolapse before dos-
ing commenced and the mice derived from PDX LK214
succumbed during the first week of treatment. These five
were excluded from the final analysis. Combining the
results of 35 mice derived from nine patient samples,
DEX+DAS treatment significantly impaired leukemia pro-
gression more than single drug DEX, DAS or control vehi-
Y. Shi et al.




Figure 5. Dasatinib (DAS) inhibits lymphocyte cell-specific kinase (LCK) and leads to cell cycle arrest. (A) SUPT1 and MOLT4 cells were treated with vehicle control
or DAS (2 mM) for 24 hours (h) and expression of total LCK, activated p-Y416SRC, total PLCy1 and activated p-Y783PLCγ1 was assessed in western blot analysis (left) or
cells were stained with Hoechst and analyzed for cell cycle status (middle and right). (B) Patient-derived xenograft (PDX) LK203 and L963 cells were treated for 24
h with 1 mM of DAS. LCK and PLCγ1 total protein and activating phospho-sites at Y416 and Y783 were assessed in western blot analyses or PDX were stained with
Hoechst and analyzed for cell cycle status. (C) The in vitro sensitivity of a panel of T-ALL cell lines to DAS was investigated and IC50 calculated. Phosflow was used to
determine the ratio of activated p-Y416SRC/total LCK. This ratio was correlated with in vitro sensitivity to DAS (R2=0.778, P=0.004). Student's t-test: **P<0.01. NB
HSB2 was excluded from this analysis, as the extreme sensitivity to DAS was caused by the presence of a unique translocation absent in all other sensitive cell lines. 
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cle as measured by hCD45 or hCD7 engraftment in
peripheral blood, bone marrow, spleen and CNS (Figure
7D-F and Online Supplementary Figure S7A). Single agent
DEX reduced CNS leukemia burden in 7 out of 9 samples,
reflecting its proven efficacy in reducing CNS relapses,27
whilst DAS showed some reduction in CNS burden in 4
out of 8 samples (Online Supplementary Figure S7B).
Combination therapy was particularly effective, with
complete eradication of measurable CNS leukemia in five
patient samples and evidence of an additive effect with
DEX in 3 out of 4 of the remaining patient samples (Online
Supplementary Figure S7B). When considering the cohort of
nine patient samples overall, combination treatment sig-
nificantly reduced leukemic infiltrates compared to con-
trol (P=0.02). Representative histology images are shown
in Figure 7G. Spleen weight was substantially reduced in
mice receiving combination treatment, compared with the
single or control treatment arms (Online Supplementary
Figure S7C and D). DEX+DAS also significantly reduced
hCD45+ or hCD7+ leukemia cell engraftment in liver tissue
of all six PDX samples analyzed (Online Supplementary
Figure S7E). The initial therapeutic advantage of
DEX+DAS in mice derived from PDX LK080 was lost at
the end of the experiment, most likely because these mice
were kept alive for 3 weeks after completion of treatment.
In the case of L907, however, the benefit of combination
treatment was not observed until the last time point
(Online Supplementary Figure S7G).
Discussion
Using a phase II-like murine trial, we demonstrate here
the efficacy of the drug combination DEX+DAS in impair-
ing expansion of human T-ALL samples. This effect is
apparent in an unselected, biologically heterogeneous,
cohort of PDX samples. This trial format recapitulates
early phase human clinical trials and indicates that this
drug combination could be widely applicable in the treat-
ment of T-ALL. Studies by Serafin et al.  first proposed a
role for this drug combination.28 Our murine trial extends
these initial observations with an extensive cohort consist-
ing of nine different PDX demonstrating treatment advan-
tage for both DEX sensitive and resistant T-ALL.
Significant superiority of DEX+DAS was demonstrated
even after exclusion of mice who reached their clinical end
points prematurely. These untoward events highlight the
practicalities of performing murine trials. 
We propose that the impaired in vivo expansion results
from a combination of cell cycle arrest as well as cell
death. Several mechanisms could provide plausible expla-
nations for the occurrence of cell cycle arrest. DAS is a
protein tyrosine kinase inhibitor which targets Abl and
SFK family members. We have confirmed that DAS effec-
tively inhibits activity of the SFK member LCK by pre-
venting phosphorylation, leading to G0/G1 arrest. DAS has
previously been shown to inhibit cyclin dependent kinase
1 (CDK1), which plays a central role in G1/S and G2/M
Figure 6. Dexamethasone (DEX) and dasatinib (DAS) act synergistically to induce cell death in T-cell acute lymphoblastic leukemia (T-ALL). (A) Cell viability of
parental SUPT1 cells (mock), shCtrl (NTC), shLCK#1 or shLCK#3 transduced SUPT1 cells upon treatment with increasing DEX concentrations (0-1699 nM). (B) Cell
viability of SUPT1 with and without DAS (left; black line, no DAS; blue line, 0.8 mM; red line, 2.0 mM) in combination with increasing concentrations of DEX (0-600
nM) as derived from the drug matrix with titration of DEX (0-600 nM) and DAS (0 - 50 uM; right). (Right) Combenefit analysis of drug matrix demonstrates drug synergy
in SUPT1 cells at clinically relevant drug concentrations. (C) (Left) LK203 cells were expanded ex vivo on OP9-DL1 feeder cells for 1 week prior to treatment with and
without DAS (black line, no DAS; blue line, 0.08 µM; red line, 2.0 mM; orange line, 10 mM) in combination with increasing concentrations of DEX (0-600 nM) as derived
from a drug matrix with DEX (0-600 nM) and DAS (0 - 50 uM) (Online Supplementary Figure S6E). (Right) Cell death analysis in LK203 cells exposed to control (Ctrl)
conditions, DAS (1 mM), DEX (100 nM) or DAS+DEX combination treatment. (D) (Left) Normalized GILZ mRNA expression in Jurkat cells after transduction with shNTC
or shLCK#3 with or without DEX exposure (100 nM). (Right) Normalized GILZ mRNA expression in Jurkat cells after exposure to Ctrl conditions, DAS 
(2 mM), DEX (100 nM) or DAS+DEX combination treatment at the same concentrations. Student's t-test: **P<0.01, ***P<0.005, ****P<0.001.
 A                                                               B
 C                                                                                                   D
transition.29 Furthermore, G1 cell cycle arrest, through
upregulation of the cyclin-dependent kinase inhibitors
p21CIP1 (CDKN1A) and p27KIP1 (CDKN1B), has been
observed after DAS treatment in acute myeloid
leukemia.30 We propose that LCK is the predominant tar-
get of DAS in this disease setting, as our shRNA screen
identified a critical role for LCK in cell proliferation in cell
lines and PDX samples. Moreover, LCK is the proposed
DAS target when blocking T-cell activation.21 Competitive
assays confirmed defective proliferation of T-ALL cells
after LCK knockdown in vitro and in vivo. We have shown
that LCK knockdown leads to G0/G1 cell cycle arrest in cell
lines and PDX. This effect was more pronounced using
DAS, a finding which could potentially be explained by
incomplete knockdown of LCK or the wide spectrum of
kinases targeted by DAS.
As reported earlier and confirmed in our studies, DAS is
cytotoxic to a small subset of T-ALL samples with IC50 val-
ues in the low nanomolar range.31 These observations
were made in T-ALL samples without kinase activating
mutations, which are seen very infrequently in T-ALL. To
the best of our knowledge, our cohort includes only one
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Figure 7. Dexamethasone (DEX) + dasatinib (DAS) synergize to impair leukemia engraftment in a Phase II-like murine trial. (A) Layout of the in vivo trial using ten
different patient-derived xenograft (PDX) samples. PDX samples were engrafted into four mice each and treated with control vehicle (Ctrl), DEX (1 mg/kg), DAS (35
mg/kg) or DEX+DAS (1 mg/kg DEX + 35 mg/kg DAS). Mice were dosed once daily, 5 times per week, for 2-3 weeks depending on clinical status of the mice. (B)
Engraftment of hCD45+ cells (%) was determined weekly in peripheral blood derived from four mice injected with PDX L809. Engraftment levels are shown starting
from day of injection (day 0) in mice receiving control vehicle (Ctrl, black), DAS (blue), DEX (green), or DEX+DAS (red). Vertical dotted lines indicate the treatment win-
dow (3 weeks) starting on day 46 and completing on day 64. Mice were culled on day 72 and analyzed for hCD45/hCD7 engraftment. (C) Western blotting of total
and phosphorylated lymphocyte cell-specific kinase (LCK) protein levels of whole cell lysates derived from the spleens of four mice injected with PDX L809 under four
different treatment arms (Ctrl, DAS, DEX or DEX+DAS) relative to the housekeeper GAPDH. (D-F) Summary of final human CD7+ engraftment (%) in peripheral blood
(D), spleen (E), and bone marrow (F) of mice treated with Ctrl (black), DAS (blue), DEX (green), or DEX+DAS (red). *P<0.05, **P<0.01, ***P<0.001. (G)
Photomicrographs of whole brain-skull sections stained with Hematoxylin & Eosin from PDX L809. (Left) Low power scout view of whole brain with area shown in all
other images marked by black box. (Centre and right) High power view (x20 objective) of meninges around the central venous sinus in mice receiving Ctrl, DAS, DEX
or DEX+DAS treatment. Red arrows mark the leukemic infiltrate. Scale bar marks 1 mm on scout view and 100 mm on high power images.
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PDX with such an activating genetic lesion (LK287,
FIP1L1-PDGFRA). Cytotoxicity to DAS is significantly
increased upon combination with DEX. Our data indicate
drug synergy between DAS and DEX at clinically relevant
concentrations. A previous, mostly in vitro, study advocat-
ed the use of DEX+DAS in GC resistant T-ALL.28 Our
extended studies indicate DEX+DAS act synergistically in
the majority of cell lines and PDX tested independent of
their prior sensitivity to DEX. The potential of DEX+DAS
to revert GC resistance is an exciting observation. GC
resistance is frequently observed in relapsed/refractory 
T-ALL,4 and DEX+DAS provide a clinically actionable
approach to re-sensitize T-ALL resistant to DEX.
The implementation of DAS into clinical management
would benefit from the identification of a reliable
response biomarker. Although LCK activation status (ratio
p-Y416SRC/LCK) strongly correlates with DAS sensitivity
in cell lines, we were unable to corroborate this observa-
tion in PDX cells. Sample size and intricacies of in vitro
assays using PDX cells could provide possible explana-
tions for these inconsistencies. Nevertheless, in vivo drug
synergy was observed in the majority of samples tested.
Of interest, drug response profiling of T-ALL samples sug-
gested SRC pathway activation may represent a response
biomarker.31
The mechanism underlying the observed drug synergy
remains to be fully elucidated. T-cell activation can be
blocked by using clinically relevant concentrations of the
tyrosine kinase inhibitor DAS, which binds to the ATP-
binding pocket of LCK thereby preventing the phosphory-
lation of the activating loop of the kinase domain 
p-Y416SRC.21,32 When DEX is combined with DAS, physio-
logical CD3+ T-cell proliferation is reduced in an additive
way.33,34 Furthermore, it has been previously suggested
that the Calcineurin/NFAT/IL-4 axis is activated in
patients exhibiting a prednisone poor response.28 We have
shown here that combination of DEX+DAS significantly
increases GILZ gene expression, reflecting increased tran-
scriptional activity of the GC receptor. We thus hypothe-
size that inhibition of LCK disrupts the TCR-GR complex
and established crosstalk between the TCR and GR path-
ways leading to dissociation and transcriptional activation
of the GR.13
To conclude, drug resistant T-ALL continues to repre-
sent an unmet clinical need. We provide further support
for the inclusion of DAS in the treatment of T-ALL. It has
been reported that DAS in combination with conventional
chemotherapy is safe and well tolerated in children and
young adults, although hematologic toxicity was signifi-
cant.35 Thus, the DEX+DAS combination should be con-
sidered in the early phase setting to evaluate toxicity and
efficacy in patients with GC resistant disease with or
without cerebral spinal fluid involvement.
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